norovirus
princip
caus
epidem
gastroenter
worldwid
strain
account
infect
major
capsid
protein
strain
evolv
rapidli
result
new
epidem
strain
alter
antigen
potenti
test
antigen
drift
may
contribut
persist
human
memori
b
cell
immort
result
human
monoclon
antibodi
mab
character
reactiv
panel
timeord
viruslik
particl
vlp
reflect
complex
exposur
histori
volunt
human
mab
group
three
vlp
reactiv
pattern
ancestr
react
exclus
earliest
vlp
eia
blockad
nvb
specif
bound
block
contemporari
vlp
nbv
exclus
react
block
variant
minerva
strain
three
mab
broad
reactiv
two
nvb
also
detect
genogroup
ii
vlp
eia
block
vlp
interact
carbohydr
ligand
nvb
crossneutr
panel
timeord
vlp
measur
vlpcarbohydr
blockad
assay
use
mutant
vlp
design
alter
predict
antigen
epitop
two
evolv
blockad
epitop
map
amino
acid
requir
bind
nvb
mab
amino
acid
essenti
bind
nvb
support
earlier
correl
antibodi
blockad
escap
carbohydr
bind
variat
data
inform
vlp
vaccin
design
provid
strategi
expand
crossblockad
potenti
chimer
vlp
vaccin
identifi
antibodi
broadli
neutral
therapeut
potenti
treatment
human
diseas
moreov
data
support
hypothesi
noroviru
evolut
heavili
influenc
antigen
variat
neutral
epitop
consequ
antibodydriven
receptor
switch
thu
protect
herd
immun
drive
forc
noroviru
molecular
evolut
norovirus
nov
lead
caus
sever
viral
gastroenter
respons
acut
gastroenter
outbreak
unit
state
europ
although
sever
diseas
usual
moder
last
day
infect
especi
virul
young
children
elderli
immunocompromis
latter
group
experienc
chronic
diarrhea
viru
shed
year
importantli
estim
peopl
die
year
noroviru
infect
primarili
children
develop
world
effect
vaccin
would
particularli
advantag
young
age
popul
militari
personnel
children
healthcar
provid
food
handler
cruis
ship
passeng
popul
develop
world
immunotherapeut
especi
need
treat
immunosuppress
popul
experienc
longterm
infect
chronic
diarrhea
lack
understand
extens
antigen
relationship
among
larg
number
noroviru
strain
complex
relationship
host
protect
immun
viru
antigen
heterogen
primari
obstacl
noroviru
vaccin
develop
norovirus
nm
icosahedr
virus
kb
singlestrand
positivesens
rna
genom
contain
three
larg
open
read
frame
orf
encod
nonstructur
protein
orf
encod
major
minor
capsid
protein
respect
express
major
capsid
protein
venezuelan
equin
enceph
vee
viru
baculoviru
result
format
viruslik
particl
vlp
compos
copi
major
capsid
protein
dimer
norovirus
group
amino
acid
sequenc
major
capsid
protein
virus
less
differ
classifi
strain
differ
genotyp
differ
genogroup
current
norovirus
group
five
genogroup
gigv
genogroup
gi
gii
respons
human
infect
subdivid
differ
genotyp
respect
structur
capsid
monom
divid
three
domain
shell
domain
form
core
particl
protrud
domain
p
extend
away
core
p
domain
subdivid
subdomain
residu
subdomain
residu
subdomain
expos
region
viral
particl
well
posit
interact
potenti
neutral
antibodi
histoblood
group
antigen
hbga
ligand
previou
studi
shown
subdomain
major
capsid
protein
strain
evolv
rapidli
result
new
epidem
strain
alter
carbohydr
ligand
bind
properti
antigen
past
two
decad
major
noroviru
outbreak
caus
strain
within
genogroup
ii
genotyp
strain
subclust
four
major
noroviru
pandem
associ
strain
character
use
molecular
epidemiolog
method
strain
respons
noroviru
outbreak
usa
outbreak
netherland
strain
replac
farmington
hill
strain
associ
noroviru
outbreak
usa
hunter
variant
detect
australia
europ
asia
hunter
strain
larg
replac
two
new
cocircul
variant
usa
europ
lauren
minerva
although
similar
minerva
genbank
access
repres
new
evolutionari
cluster
phylogeni
virus
recent
new
gii
variant
new
orlean
predomin
outbreak
strain
although
minerva
continu
circul
low
level
varieti
studi
use
time
order
human
outbreak
sera
mous
monoclon
antibodi
support
hypothesi
norovirus
undergo
antigen
variat
variat
contribut
emerg
new
outbreak
strain
time
howev
lack
cell
cultur
small
anim
model
human
noroviru
cultiv
restrict
studi
neutral
antibodi
epitop
circumv
problem
highli
inform
vitro
assay
develop
measur
abil
antibodi
block
bind
vlp
carbohydr
ligand
assay
highli
sensit
differenti
noroviru
strain
similar
distinguish
enzym
immunoassay
eia
clinic
relev
blockad
assay
surrog
neutral
assay
confirm
infect
chimpanze
norwalk
virusinfect
human
nov
strain
hemagglutin
rbc
high
blockad
antibodi
titer
prevent
hemagglutin
also
correl
protect
diseas
human
use
human
noroviru
outbreak
sera
vlpimmun
mous
sera
mous
mab
earli
gii
strain
antigen
indistinguish
eia
surrog
neutral
assay
vlp
strain
circul
post
significantli
less
reactiv
sera
direct
earlier
strain
reactiv
mous
mab
direct
convers
select
mous
mab
gener
react
vlp
circul
later
blockad
epitop
found
common
gii
prior
work
other
predict
antibodi
epitop
use
bioinformat
techniqu
expect
discreet
amino
acid
repeatedli
identifi
potenti
evolv
epitop
particular
residu
consist
identifi
put
epitop
chang
epidem
strain
addit
surfac
residu
also
predict
potenti
antibodi
epitop
amino
acid
tend
cluster
loop
ridg
subdomain
antibodi
interact
would
access
beyond
bioinformat
predict
studi
shown
empir
evid
map
antigen
chang
allen
et
al
compar
reactiv
five
monoclon
antibodi
pre
epidem
strain
identifi
conform
epitop
compos
residu
carbohydr
blockad
potenti
antibodi
report
role
site
escap
herd
immun
unclear
howev
find
residu
antigen
import
support
previous
publish
work
identifi
amino
acid
antigen
determin
farmington
hill
strain
use
mous
mab
molecular
biolog
approach
exchang
predict
epitop
strain
backbon
clearli
identifi
amino
acid
compris
evolv
blockad
epitop
exchang
amino
acid
confer
bind
mab
recogn
extend
approach
also
confirm
amino
acid
constitut
farmington
hillsspecif
blockad
epitop
empir
studi
support
valid
use
comput
analysi
guid
noroviru
epitop
studi
compar
reactiv
polyclon
sera
collect
immun
mice
infect
human
suggest
antigen
variat
within
norovirus
develop
mous
mab
differ
timeord
vlp
greatli
facilit
progress
toward
understand
complex
antigen
relat
among
strain
clearli
demonstr
antigen
variat
time
epidem
strain
howev
maxim
defin
mechanist
relationship
exist
antigen
variat
immun
hbga
bind
pattern
note
norovirus
context
natur
infect
histori
cross
reactiv
pattern
blockad
respons
epitop
target
human
monoclon
antibodi
need
robust
approach
exist
isol
human
monoclon
antibodi
elicit
follow
viru
infect
use
human
pbmc
norovirus
princip
caus
epidem
gastroenter
worldwid
strain
account
infect
major
capsid
protein
strain
evolv
rapidli
result
new
epidem
strain
alter
antigen
site
defin
site
prepar
first
human
monoclon
antibodi
hu
mab
norovirus
immort
memori
b
cell
character
antibodi
reactiv
carbohydr
blockad
respons
across
year
panel
timeord
viruslik
particl
vlp
reflect
complex
exposur
histori
patient
human
mab
group
three
vlp
reactiv
pattern
broad
contemporari
ancestr
also
identifi
locat
sever
defin
epitop
evolv
time
drive
antigen
chang
data
indic
antibodi
target
site
block
carbohydr
bind
like
select
emerg
new
strain
escap
herd
immun
recogn
uniqu
carbohydr
entri
result
new
outbreak
diseas
vulner
human
popul
importantli
studi
critic
inform
ration
design
broadli
activ
vaccin
immunotherapeut
treatment
noroviru
diseas
sourc
memori
b
cell
creat
panel
human
mab
direct
strain
compar
reactiv
mab
panel
timeord
vlp
use
eia
surrog
neutral
assay
identifi
one
novel
broadli
cross
reactiv
antibodi
differenti
block
vlp
interact
carbohydr
ligand
potenti
immunotherapeut
treatment
acut
chronic
diseas
also
defin
uniqu
antibodi
interact
two
differ
surfac
expos
epitop
evolv
time
importantli
antigen
variat
one
epitop
correl
chang
carbohydr
ligand
bind
pattern
time
support
propos
relationship
epitop
escap
human
herd
immun
chang
hbga
usag
viru
dock
addit
defin
first
human
monoclon
antibodi
therapeut
potenti
treat
acut
chronic
nov
infect
data
support
hypothesi
noroviru
evolut
result
antigen
drift
neutral
epitop
consequ
antibodydriven
hbga
receptor
switch
thu
protect
herd
immun
drive
forc
noroviru
evolut
develop
mous
mab
differ
timeord
vlp
greatli
facilit
understand
complex
antigen
relat
strain
clearli
demonstr
antigen
variat
time
epidem
strain
howev
understand
human
noroviru
antibodi
respons
essenti
understand
complex
relationship
host
immun
viru
antigen
chang
also
ration
vaccin
design
base
defin
neutral
epitop
therefor
develop
panel
human
noroviru
monoclon
antibodi
begin
character
antibodi
reactiv
nativ
viru
host
natur
infect
condit
note
noroviru
preexposur
histori
human
volunt
unknown
infer
human
sera
crossreact
antibodi
bind
blockad
pattern
use
timeord
vlp
repres
differ
outbreak
pandem
strain
tabl
plasma
pbmc
sampl
healthi
individu
collect
earli
plasma
bind
titer
measur
eia
panel
differ
noroviru
vlp
repres
gi
gii
strain
figur
major
test
sampl
react
eia
variabl
titer
panel
vlp
test
figur
one
sampl
donor
nvb
shown
react
strongli
gii
vlp
therefor
chosen
charact
figur
figur
significantli
antibodi
need
block
bind
mgml
bind
mgml
figur
support
hypothesi
subtl
antigen
differ
exist
strain
differ
blockad
sensit
gii
nvb
provid
first
evid
subtl
antigen
diverg
two
minerva
variant
caus
widespread
outbreak
global
observ
support
human
mab
nvb
nvb
reactiv
profil
singledilut
eia
nvb
specif
react
minim
variant
minerva
test
vlp
tabl
figur
accordingli
nvb
requir
antibodi
block
interact
mgml
requir
block
interact
mgml
figur
b
comparison
nvb
specif
recogn
minerva
variant
eia
tabl
figur
interact
variant
pgm
ligand
effici
block
nvb
figur
tabl
figur
despit
broad
eia
reactiv
nvb
figur
three
human
mab
indic
exist
conserv
epitop
past
twentyf
year
across
three
pandem
strain
could
serv
target
broadbas
vaccin
design
importantli
nvb
repres
first
potenti
broad
spectrum
immunetherapeut
nov
addit
vlppgm
interact
blockad
assay
human
mab
also
test
blockad
vlpsynthet
biotinyl
hbga
bihbga
interact
abil
block
vlp
hemagglutin
rbc
regardless
substrat
pgm
bihbga
doserespons
profil
blockad
antibodi
vlp
similar
compar
figur
f
although
titer
rel
high
mgml
nvb
respect
compar
amount
antibodi
need
block
strainspecif
mab
mgml
nvb
repeat
test
pgm
substrat
replic
find
synthet
carbohydr
substrat
figur
b
addit
measur
antibodi
blockad
abil
use
rbc
vlp
bind
substrat
previou
work
demonstr
norwalk
viru
vlp
hemagglutin
ha
rbc
interact
disrupt
antibodi
found
polyclon
serum
hemagglutin
inhibit
hai
hai
titer
serum
correl
antibodi
blockad
vlpbihbga
interact
determin
find
could
extend
studi
gii
previou
work
mousederiv
antinoroviru
mab
suggest
blockad
epitop
conform
depend
test
effect
protein
conform
human
mab
bind
use
western
blot
eia
analysi
compar
antibodi
bind
vlp
p
protein
p
protein
compos
ctermin
portion
major
capsid
protein
amino
acid
express
p
protein
e
coli
result
small
particl
format
estim
consist
p
dimer
reportedli
maintain
vlp
characterist
carbohydr
antibodi
bind
studi
none
human
mab
recogn
either
denatur
vlp
p
protein
western
blot
analysi
suggest
epitop
antibodi
conform
depend
data
shown
surprisingli
half
mab
recogn
vlp
figur
eia
also
recogn
p
protein
eia
figur
nvb
extend
broad
reactiv
p
protein
wherea
nvb
indic
minimum
three
crossreact
epitop
must
exist
nvb
also
detect
p
protein
eia
neither
minerva
variant
mab
recogn
p
protein
even
protein
concentr
standard
eia
condit
mgml
coat
protein
seven
mab
detect
increas
concentr
vlp
linear
dose
respons
signal
satur
mgml
vlp
mab
concentr
held
mgml
standard
eia
antibodi
titer
figur
antibodi
reactiv
p
protein
satur
lower
protein
concentr
vlp
optic
densiti
linear
rang
assay
compar
figur
suggest
even
among
mab
bind
p
protein
conformationbas
epitop
may
limit
way
observ
vlp
data
suggest
two
import
point
first
mab
epitop
highli
sensit
conform
secondli
principl
p
protein
conform
ident
vlp
least
critic
blockad
epitop
evolut
norovirus
assess
period
time
compar
strain
compar
sequenc
site
variat
subdomain
note
site
map
onto
crystal
structur
pdomain
dimer
strain
surfaceexpos
site
variat
examin
determin
residu
may
close
enough
constitut
singl
epitop
five
epitop
predict
base
upon
variat
figur
epitop
encod
signific
amino
acid
chang
time
also
demonstr
evolv
blockad
epitop
use
mous
mab
figur
epitop
conform
locat
top
capsid
proxim
hbga
bind
pocket
six
variabl
site
close
region
put
epitop
suggest
residu
may
work
concert
chang
local
structur
epitop
variabl
surfaceexpos
residu
includ
posit
note
epitop
continu
evolv
extant
strain
wherebi
amino
acid
posit
seem
vari
extens
strain
amino
acid
replac
observ
posit
epitop
b
predict
base
upon
two
variabl
residu
posit
residu
buri
dimer
interfac
two
chain
pattern
variat
site
suggest
play
import
role
evolut
novel
strain
perhap
evolv
replac
allow
surfac
expos
residu
surfac
expos
epitop
dramat
chang
physiochem
properti
amino
acid
replac
residu
make
variabl
residu
put
epitop
c
put
conform
depend
epitop
surfac
later
edg
capsid
directli
proxim
hbga
bind
pocket
suggest
epitop
may
play
role
receptor
switch
along
epitop
epitop
compris
tabl
three
variabl
residu
posit
first
report
crystal
structur
norovirus
region
report
secondari
hbga
bind
site
howev
locat
epitop
surfac
capsid
directli
proxim
hbga
bind
site
suggest
like
play
role
receptor
switch
escap
herd
immun
perhap
simultan
epitop
close
enough
hbga
bind
pocket
contribut
inhibit
carbohydr
bind
yet
variabl
enough
suggest
target
immun
respons
put
epitop
e
compris
variabl
residu
surfac
expos
region
later
hbga
bind
pocket
epitop
residu
vari
everi
major
epidem
strain
suggest
hot
spot
emerg
immunolog
novel
strain
epitop
e
blockad
antibodi
epitop
put
epitop
later
hbga
bind
pocket
indic
antibodi
target
interior
region
capsid
surfac
suggest
epitop
may
present
subdomain
variabl
residu
necessarili
identifi
boundari
put
epitop
moreov
nearli
imposs
predict
surfac
area
put
epitop
sequenc
analysi
alon
therefor
expand
put
epitop
includ
residu
within
variabl
site
epitop
predict
figur
describ
mab
indic
least
five
uniqu
overlap
blockad
epitop
differ
specif
earli
strain
specif
contemporari
strain
specif
minervavari
strain
specif
genogroup
ii
strain
specif
strain
specif
use
capsid
sequenc
guid
mutant
vlp
design
contain
chimer
combin
predict
evolv
epitop
figur
epitop
exchang
vlp
morpholog
intact
electron
microscopi
visual
retain
abil
bind
pgm
figur
b
confirm
chimer
vlp
structur
integr
epitop
mutant
vlp
compar
wild
type
strain
vlp
reactiv
donor
plasma
sampl
consist
high
eia
reactiv
vlp
tabl
figur
donor
plasma
react
across
panel
epitopeexchang
mutant
vlp
figur
donor
plasma
abl
block
epitopeexchang
vlp
bind
pgm
figur
c
exchang
epitop
except
epitop
either
backbon
c
result
significantli
differ
valu
compar
parent
strain
figur
tabl
exchang
epitop
backbon
result
exchang
blockad
phenotyp
observ
epitopespecif
mab
exchang
epitop
two
parent
backbon
result
chimer
vlp
block
significantli
less
plasma
parent
mgml
compar
mgml
chimer
vlp
block
signif
figur
tabl
bar
sem
tabl
individu
data
suggest
epitop
may
import
evolv
neutral
epitop
blockad
respons
signific
enough
detect
polyclon
antibodi
respons
agre
assumpt
epitopeexchang
mutant
unlik
identifi
epitop
crossreact
mab
nvb
react
entir
panel
chimer
vlp
eia
figur
contrast
strainspecif
mab
display
differenti
eia
reactiv
exchang
epitop
tabl
exchang
epitop
elimin
nvb
blockad
potenti
figur
b
figur
b
bind
restor
wild
type
level
mgml
significantli
higher
blockad
pgm
mgml
figur
tabl
eia
blockad
data
clearli
indic
epitop
critic
bind
nvb
suggest
amino
acid
import
compon
evolv
blockad
epitop
addit
modul
vlpcarbohydr
ligand
bind
interestingli
epitop
singl
amino
acid
chang
explain
highli
conserv
bind
blockad
respons
note
across
vlp
ancestr
strain
display
signific
antigen
variat
across
residu
togeth
data
map
evolv
blockad
epitop
recogn
four
strainexclus
human
mab
describ
studi
figur
norovirus
recogn
lead
caus
viral
foodborn
gastroenter
success
vaccin
program
develop
rotaviru
focu
shift
noroviru
primari
caus
agent
sever
childhood
diarrhea
result
yearli
estim
million
episod
pediatr
gastroenter
develop
nation
death
develop
nation
elderli
immunocompromis
also
suffer
sometim
lifethreaten
chronic
longterm
noroviru
diarrheal
diseas
character
malnutrit
dehydr
hiv
infect
patient
chronic
noroviru
diarrheal
diseas
associ
persist
noroviru
infect
econom
diseas
burden
noroviru
outbreak
within
care
facil
estim
singl
event
statist
emphas
critic
need
noroviru
vaccin
although
recent
report
strongli
support
develop
use
efficaci
noroviru
vaccin
human
primari
obstacl
success
vaccin
lack
definit
correl
protect
coupl
extrem
antigen
variat
across
mani
noroviru
strain
fact
exist
longterm
protect
immun
noroviru
infect
remain
controversi
within
field
human
challeng
studi
conduct
molecular
diagnost
infect
refin
immun
respons
assay
indic
volunt
could
reinfect
noroviru
strain
suggest
noroviru
infect
induc
longterm
protect
howev
recent
report
identifi
immun
respons
noroviruschalleng
uninfect
volunt
necessit
qualif
earli
observ
acknowledg
find
may
compromis
assay
limit
andor
overwhelm
challeng
dose
comparison
low
noroviru
infecti
dose
clearli
defin
relationship
preexposur
histori
blockad
antibodi
respons
cell
immun
viru
evolut
compon
protect
immun
repres
key
challeng
futur
vaccin
therapeut
design
addit
clinic
applic
therapi
diagnosi
monoclon
antibodi
also
proven
superior
tool
studi
viral
antigen
evolut
treatment
acut
viral
diseas
human
character
neutral
mab
escapemut
fundament
identifi
epitop
associ
viru
receptor
usag
pathogenesi
fit
manuscript
isol
character
first
human
mab
norovirus
deriv
healthi
donor
whose
preexposur
histori
unknown
number
uniqu
human
monoclon
antibodi
patient
accur
reflect
high
preval
noroviru
infect
seen
human
popul
past
year
moreov
distinct
antibodi
cross
reactiv
pattern
support
hypothesi
genotyp
undergo
antigen
variat
correl
loss
antibodi
blockad
activ
emerg
new
epidem
noroviru
strain
also
chang
carbohydr
ligand
bind
pattern
time
importantli
antibodymedi
antigen
drift
strain
coupl
mucos
iga
cell
respons
challeng
uninfect
volunt
strongli
support
exist
longterm
protect
immun
noroviru
strain
fact
uniqu
antibodi
reactiv
pattern
character
herein
like
explain
archeolog
immun
record
success
wave
contemporari
infect
individu
time
impli
success
vaccin
design
possibl
previous
propos
group
other
previous
identifi
two
immunolog
respons
associ
protect
infect
noroviruschalleng
volunt
earli
day
postexposur
salivari
iga
respons
genet
suscept
volunt
correl
protect
norwalk
viru
infect
earli
h
respons
correl
protect
snow
mountain
viru
infect
histor
role
igg
noroviru
protect
unclear
adulthood
popul
posit
antinoroviru
igg
noroviru
strain
within
genogroup
share
high
degre
antigen
crossreact
measur
eia
fact
like
skew
function
interpret
role
serum
igg
titer
suscept
infect
andor
infect
outcom
although
carbohydr
ligand
blockad
antibodi
respons
suggest
correl
protect
immun
nt
recent
blockad
respons
correl
definit
protect
clinic
diseas
infect
importantli
surrog
neutral
assay
specif
enough
differenti
noroviru
strain
similar
distinguish
eia
differ
key
antigen
site
human
rechalleng
studi
use
viral
inoculum
necessari
confirm
associ
blockad
igg
respons
protect
repeat
noroviru
infect
find
support
clinic
relev
antibodi
blockad
assay
correl
protect
immun
monoclon
antibodi
coupl
blockad
assay
power
tool
elucid
antigen
relationship
strain
mous
mab
provid
insight
antigen
structur
data
manuscript
argu
human
mab
offer
consider
advantag
includ
immunolog
record
bcell
immun
follow
repeat
infect
b
relationship
antibodi
blockad
respons
antigen
variat
c
relationship
immun
select
carbohydr
ligand
reactiv
relationship
earli
infect
downstream
immun
e
epitop
map
focus
mab
clinic
relev
strain
one
key
find
direct
relationship
antigii
figur
given
lack
cross
reactiv
later
strain
like
explan
nvb
deriv
longterm
memori
plasma
cell
elicit
year
earlier
support
idea
examin
human
monoclon
antibodi
influenza
also
identifi
antibodi
variant
recogn
ancestr
contemporari
isol
exclus
blockad
reactiv
nvb
support
potenti
longterm
protect
immun
nvb
first
antibodi
identifi
clearli
demonstr
antigen
differ
gii
suggest
antigen
variat
may
subtli
contribut
emerg
us
pandem
strain
ancestr
strain
human
monoclon
antibodi
clearli
identifi
two
evolv
epitop
surfac
vlp
epitop
confirm
evolv
antibodi
blockad
epitop
use
chimer
vlp
contain
mixtur
epitop
deriv
earli
contemporari
strain
recogn
epitop
structur
defin
epitop
support
need
structur
studi
defin
exact
mab
bind
site
vlp
moreov
focus
discret
region
vari
residu
residu
within
repres
approxim
primari
site
may
influenc
directli
amino
acid
replac
figur
howev
ab
bind
site
report
much
larger
suggest
epitop
predict
may
actual
work
concert
form
larger
ab
recognit
site
expand
put
epitop
identifi
residu
less
variabl
howev
exact
role
vari
residu
play
evolut
less
clear
case
variat
may
requir
encod
chang
necessari
replac
primari
site
addit
structur
analys
conduct
use
model
p
dimer
repres
th
vlp
structur
surfac
interact
epitop
context
superstructur
determin
therefor
observ
indic
complex
natur
nov
ab
epitop
requir
research
defin
specif
boundari
residu
regul
ab
bind
predict
five
put
epitop
allow
us
gain
sever
import
insight
noroviru
evolut
discret
site
variat
occur
noroviru
capsid
either
directli
surfac
later
hbga
bind
site
secondari
variabl
site
within
primari
variabl
site
secondari
site
could
also
contribut
epitop
remodel
mani
put
expand
epitop
overlap
suggest
two
highli
variabl
epitop
may
work
concert
escap
antibodi
respons
put
epitop
buri
may
exert
effect
structur
alter
interior
fold
space
allow
unconvent
replac
toler
underli
amino
acid
network
like
preserv
function
core
capsid
protein
regul
variabl
residu
escap
hbga
bind
may
intim
link
via
underli
regulatori
network
amino
acid
preserv
function
integr
capsid
core
epitop
like
includ
vari
amino
acid
residu
potenti
undefin
nearbi
residu
map
blockad
epitop
gii
figur
time
unclear
mani
amino
acid
epitop
need
mediat
escap
mutant
phenotyp
complet
resist
antibodi
blockad
howev
clear
epitop
vari
site
conserv
major
target
blockad
antibodi
respons
although
correl
comparison
epitop
variat
along
residu
proxim
appear
evolv
time
suggest
chang
posit
might
contribut
escap
phenotyp
residu
play
direct
role
variat
figur
howev
minor
replac
posit
like
essenti
remodel
local
structur
neighborhood
profound
chang
toler
support
sensit
epitop
local
environ
mab
recogn
epitop
differenti
vlp
p
dimer
p
protein
p
dimer
dimer
truncat
form
major
capsid
protein
compos
residu
pdimer
wide
use
determin
crystallograph
structur
novhbga
interact
consid
accur
reflect
vlp
surfac
topolog
p
particl
assembl
higher
order
structur
compos
vari
copi
p
dimer
subvir
particl
report
similar
characterist
vlp
propos
candid
vaccin
platform
knowledg
first
immunolog
character
pdimer
vs
vlp
use
monoclon
antibodi
deriv
human
infect
pdimer
deriv
lost
bind
mab
nvb
mab
recogn
epitop
gii
p
dimer
bind
epitop
bind
mab
nvb
broadli
crossblockad
mab
nvb
retain
recent
pparticl
vaccin
shown
less
robust
induc
strong
blockad
respons
compar
intact
vlp
perhap
loss
blockad
epitop
higher
order
structur
specul
recogn
virion
breath
suggest
possibl
pdimer
pparticl
may
becom
lock
slightli
less
immunolog
reactiv
state
affect
blockad
epitop
virion
surfac
data
absolut
underscor
critic
import
determin
structur
sever
human
mab
appropri
vlp
epitop
either
cryoem
crystallographi
inform
target
mutagenesi
identifi
role
key
residu
regul
antigen
antibodi
escap
epitop
conform
epitop
compris
vari
amino
acid
like
nearbi
residu
less
clearli
defin
howev
addit
map
crystallograph
studi
need
clarifi
epitop
structur
emerg
pandem
gii
figur
previous
residu
implic
regul
noroviru
vlpcarbohydr
ligand
bind
interact
identif
epitop
human
antibodi
blockad
epitop
chang
time
provid
direct
support
previou
hypothesi
escap
protect
herd
immun
may
drive
chang
carbohydr
ligand
bind
affin
time
potenti
retarget
viru
infect
differ
human
popul
data
indic
like
influenza
success
noroviru
vaccin
regimen
requir
period
popul
sampl
identifi
futur
strain
inclus
next
year
vaccin
formul
unlik
strategi
employ
influenza
viru
global
surveil
program
noroviru
popul
sampl
alreadi
begun
monitor
system
detect
nov
infect
establish
unit
state
europ
japan
identif
evolv
antigen
epitop
further
understand
noroviru
pathogenesi
provid
target
epitop
may
use
surveil
predict
new
strain
emerg
identif
conserv
epitop
also
inform
diagnost
potenti
therapeut
reagent
develop
design
monoclon
antibodi
nvb
recogn
epitop
conserv
among
strain
nvb
enhanc
gii
vlp
recognit
bind
vlp
also
gii
vlp
unabl
block
vlppgm
interact
high
conserv
nvb
epitop
suggest
epitop
highli
resist
antigen
variat
within
gii
strain
make
mab
potenti
valuabl
diagnost
reagent
gii
strain
caus
noroviru
outbreak
unidentifi
epitop
nvb
clearli
differ
epitop
recogn
nvb
conserv
throughout
strain
nvb
recogn
vlp
importantli
exhibit
blockad
activ
entir
panel
timeord
vlp
pgm
bihbga
emphas
differ
two
quantit
blockad
assay
qualit
hai
assay
ha
inhibit
nvb
note
blockad
assay
true
measur
neutral
nvb
potenti
therapeut
reagent
base
broad
blockad
potenti
fact
natur
human
antibodi
clearli
effect
nvb
prevent
treat
ill
determin
empir
although
one
blockadeepitop
specif
mab
lower
valuessteep
hill
constant
may
effect
select
strain
neutral
breadth
strain
neutral
like
limit
mab
number
viral
diseas
current
treat
mab
includ
rsv
cmv
enteroviru
howev
antirsv
human
mab
palivizumab
fda
approv
prophylact
use
human
outbreak
set
chronic
infect
patient
antinov
mab
could
deliv
symptom
begin
protect
ill
could
use
care
facil
militari
cruis
industri
given
acut
clinic
diseas
window
less
like
therapeut
antibodi
provid
relief
individu
experienc
acut
infect
howev
therapeut
antibodi
may
offer
opportun
amelior
symptomat
diseas
chronic
infect
discoveri
broadli
cross
reactiv
cross
blockad
human
mab
dictat
need
new
approach
map
epitop
current
experiment
approach
design
identifi
epitop
chang
time
provid
insight
broadli
conserv
epitop
locat
identif
epitop
recogn
nvb
import
implic
success
vaccin
design
new
panel
mutat
vlp
approach
need
character
epitop
futur
nov
signific
human
pathogen
caus
consider
morbid
mortal
worldwid
develop
mous
mab
differ
timeord
vlp
greatli
facilit
progress
toward
understand
complex
antigen
relationship
strain
clearli
demonstr
antigen
variat
time
epidem
strain
expand
observ
use
human
mab
isol
healthi
adult
donor
like
experienc
multipl
noroviru
infect
throughout
hisher
lifetim
identif
highli
signific
vari
antigen
epitop
influenc
vlpcarbohydr
ligand
interact
provid
import
new
insight
vaccin
design
develop
therapeut
target
noroviru
virion
exampl
antibodi
repres
first
antinoroviru
human
mab
character
confirm
find
studi
use
mous
mab
support
antigen
drift
linkag
vari
carbohydr
ligand
bind
profil
within
norovirus
demonstr
nov
vari
epitop
exchang
timeord
vlp
provid
robust
platform
expand
antigen
blockad
cross
reactiv
futur
vaccin
candid
use
approach
identifi
two
surfaceexpos
antibodi
blockad
epitop
vari
time
differenti
recogn
four
seven
human
mab
also
identifi
three
antibodi
recogn
either
overlap
three
uniqu
highli
conserv
epitop
within
vlp
data
continu
support
hypothesi
noroviru
longterm
protect
immun
respons
elicit
follow
acut
infect
concept
essenti
effect
vaccin
design
anticip
full
understand
vari
antigen
blockad
epitop
nov
may
help
predict
emerg
new
epidem
strain
simultan
identifi
key
reformul
vaccin
design
protect
public
health
contemporari
emerg
epidem
strain
futur
divers
panel
vlp
repres
gii
noroviru
strain
epitop
mutant
assembl
previous
report
design
epitop
exchang
chimer
vlp
first
identifi
surfac
expos
residu
cluster
vari
time
synthes
seri
chimer
gene
exchang
put
epitop
gii
vlp
construct
except
synthet
deriv
construct
insert
directli
vee
replicon
vector
product
viru
replicon
particl
vrp
previous
describ
group
vlp
express
vrpinfect
bhk
cell
purifi
veloc
sediment
sucros
store
new
orlean
vlp
express
baculoviru
system
purifi
cesium
chlorid
gradient
centrifug
kind
gift
dr
jan
vinj
center
diseas
control
prevent
atlanta
ga
vlp
protein
concentr
determin
bca
protein
assay
pierc
rockford
il
vlp
prepar
puriti
averag
sdspage
analysi
earli
follow
written
consent
blood
sampl
donor
collect
adult
healthi
donor
lugano
basel
blood
bank
switzerland
peripher
blood
mononuclear
cell
pbmc
plasma
isol
cryopreserv
day
use
pbmc
donor
figur
individu
born
thaw
igg
memori
b
cell
isol
use
microbead
miltenyi
follow
cell
sort
describ
cell
immort
cellswel
multipl
cultur
use
ebv
presenc
cpg
oligodeoxynucleotid
microsynth
irradi
allogen
pbmc
week
cultur
supernat
screen
presenc
norovirusspecif
mab
eia
vlp
posit
cultur
clone
limit
dilut
antibodi
recov
supernat
purifi
use
protein
affin
chromatographi
final
desalt
pb
use
hitrap
fastdesalt
column
human
mab
reactiv
determin
eia
report
briefli
plate
coat
mgml
vlp
pb
addit
mgml
purifi
igg
donor
plasma
primari
antibodi
incub
follow
antihuman
iggalkalin
phosphatas
color
develop
pnpp
substrat
solut
sigma
chemic
st
loui
mo
step
follow
wash
antibodi
dilut
dri
milk
data
shown
repres
averag
least
three
replic
repres
similar
data
least
two
independ
trial
establish
eia
use
new
mab
includ
pbscoat
well
neg
control
polyclon
antinoroviru
human
sera
posit
control
antibodi
consid
posit
reactiv
mean
optic
densiti
background
subtract
vlpcoat
well
greater
three
time
mean
optic
densiti
pbscoat
well
screen
donor
plasma
sampl
bind
titer
plasma
respect
coat
vlp
determin
eia
describ
measur
plasma
dilut
requir
achiev
maxim
bind
eia
reactiv
p
protein
amino
acid
measur
similarli
reactiv
vlp
p
protein
kind
gift
bv
prasad
baylor
colleg
medicin
houston
tx
pig
gastric
mucin
type
iii
pgm
sigma
chemic
valid
substrat
nov
vlp
antibodyblockad
assay
pgm
contain
rel
high
level
h
antigen
moder
level
lewi
antigen
vlp
use
blockad
assay
studi
bind
pgm
synthet
bihbga
bind
pgm
consist
synthet
bihbga
bind
profil
h
antigen
lewi
antigen
contain
molecul
blockad
assay
pgm
solvat
pb
mgml
coat
onto
eia
plate
mgml
pb
hour
block
night
dri
milk
vlp
mgml
pretreat
decreas
concentr
test
mab
donor
plasma
hour
room
temperatur
ad
carbohydr
ligandco
plate
hour
bound
vlp
detect
rabbit
antigii
noroviru
polyclon
sera
made
hyperimmun
either
cocktail
gii
vlp
follow
antirabbit
igghrp
ge
healthcar
color
develop
ultra
tmb
elisa
hrp
substrat
solut
thermofish
percent
control
bind
defin
bind
level
presenc
antibodi
pretreat
compar
bind
level
absenc
antibodi
pretreat
multipli
incub
done
room
temperatur
step
follow
wash
tween
reagent
dilut
dri
milk
antibodi
test
blockad
potenti
panel
vlp
twofold
serial
dilut
rang
mg
ml
addit
concentr
blockad
antibodi
test
need
complet
sigmoid
doserespons
curv
blockad
synthet
bihbga
glycotech
gaithersburg
md
assay
done
describ
pgm
follow
except
bihbga
bound
neutriavidin
coat
plate
pierc
mgml
one
hour
prior
addit
mgml
vlp
h
report
mean
control
bind
reflect
result
least
two
independ
experi
dilut
test
least
duplic
antibodi
design
blockad
antibodi
vlp
least
control
bind
inhibit
mg
ml
antibodi
blockad
data
fit
valu
calcul
use
sigmoid
dose
respons
analysi
nonlinear
data
graphpad
prism
wwwgraphpadcom
valu
vlp
compar
use
oneway
anova
dunnett
post
test
least
three
valu
compar
unpair
ttest
two
valu
compar
differ
consid
signific
p
valu
test
antibodi
bind
prevent
detector
antibodi
bind
vlp
instead
vlp
bind
pgm
select
blockad
assay
perform
without
use
detector
antibodi
instead
develop
directli
antihuman
igghrp
antibodi
test
way
give
two
respons
bellshap
respons
curv
antibodi
blockad
sigmoid
shape
curv
antibodi
blockad
data
indic
amount
human
mab
directli
block
vlp
bind
pgm
note
vlp
concentr
blockad
assay
low
nanomolar
rang
therefor
discrimin
antibodi
subnanomolar
affin
hai
assay
perform
report
vlp
ngreaction
pretreat
antibodi
describ
blockad
assay
addit
rbc
ph
hai
titer
determin
lowest
antibodi
concentr
complet
prevent
nov
vlpinduc
ha
visual
amino
acid
sequenc
gii
capsid
individu
align
p
domain
sequenc
use
domain
dimer
xray
crystal
structur
pdb
access
use
templat
gener
homolog
model
homolog
model
gener
use
program
model
avail
via
max
planck
institut
bioinformat
toolkit
http
toolkittuebingenmpgd
structur
model
analyz
compar
figur
gener
use
mac
pymol
delano
scientif
